Arcturus Therapeutics Holdings Inc (ARCT) is around the top of the Biotechnology industry according to InvestorsObserver. ARCT received an overall rating of 50, which means that it scores higher than 50 percent of all stocks. Arcturus Therapeutics Holdings Inc also achieved a score of 82 in the Biotechnology industry, putting it above 82 percent of Biotechnology stocks. Biotechnology is ranked 107 out of the 148 industries.
Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 50 would rank higher than 50 percent of all stocks.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.
Arcturus Therapeutics Holdings Inc (ARCT) stock is down -7.87% while the S&P 500 has gained 0.56% as of 9:53 AM on Monday, Jun 21. ARCT is down -$2.76 from the previous closing price of $35.09 on volume of 100,649 shares. Over the past year the S&P 500 is higher by 34.39% while ARCT is down -20.57%. ARCT lost -$4.86 per share the over the last 12 months.
Click Here to get the full Stock Score Report on Arcturus Therapeutics Holdings Inc (ARCT) Stock.
Recommendation and review posted by G. Smith
